Clinical Trial Update: Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update exploring nivolumab in combination with EGF816 and with INC280 for previously treated non-small cell lung cancer; study terminated with pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• EGF816
• INC280
• nivolumab (nivolumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: TERMINATED | Results posted: 2021-06-15